SAN FRANCISCO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NAS: GILD) today announced data from the Phase 4 TERISA (Type 2 Diabetes Evaluation of Ranolazine In Subjects With Chronic Stable Angina) study, ...

Palo Alto-based CV Therapeutics won U.S. approval to promote its only marketed drug, Ranexa, as an initial treatment for chronic chest pain, broadening the potential use. The Food and Drug ...

FDA Approves CV Therapeutics, Inc Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial ...

The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials. Participants in the MERLIN TIMI-36 study received current standard therapy, ...

PALO ALTO, Calif., Aug. 15 CV Therapeutics, Inc.(Nasdaq: CVTX) announced today that new guidelines, developed jointly by theAmerican College of Cardiology Foundation and the American Heart ...

The FDA has approved Ranexa (ranolazine extended-release tablets, from CV Therapeutics) for the first-line treatment of chronic angina. The labeling has been updated to show that Ranexa reduces ...

The mechanism of action described in the labeling for Ranexa (ranolazine extended-release tablets, from CV Therapeutics) has been updated to describe the ability of ranolazine to inhibit the late ...

The US Food and Drug Administration has approved a new, first line indication for CV Therapeutics anti-angina drug Ranexa (ranolazine). The US Food and Drug Administration has approved a new, first ...

CV Therapeutics never gained much traction with its heart-drug Ranexa, but now it's got a takeover bid that would let shareholders cash out. The biotech firm, however, is playing hard to get. The Palo ...